SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Protein binding of rifampicin is not saturated when using high-dose rifampicin- Carlijn Litjens, MScView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Pharmacodynamic Correlates of Linezolid Activity and Toxicity in a Mouse TB Model- Kristina Bigelow, MSView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Clinical Validation of Intracellular Pharmacodynamic (PDi) based modelling for the prediction of Fluoroquinolone activity against TB- Ghaith Aljayyoussi, PhDView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Model-based meta-analysis of rifampicin exposure and mortality in phase II tuberculosis meningitis trials- Elin SvenssonView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018High peak rifampicin concentrations accelerate the slow phase of bacterial elimination in tuberculosis patients- Antal MartineczView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Treatment of Multi-Drug Resistant TB- Robert Horsburgh, MDView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Cycloserine in TB Patients- Charles Peloquin, PharmDView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Clofazimine pharmacokinetics in South African patients with drug-resistant tuberculosis-Sean Wasserman, MBChB, MMedView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Fluoroquinolones in the treatment of multidrug-resistant tuberculosis: experience from three US TB treatment centers- Charles Peloquin, PharmDView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Higher rifampicin and isoniazid concentrations in epithelial lining fluid are associated with improved response to treatment in pulmonary TB- Andrew McCallum, MBChBView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention- Anthony Podany, PharmDView Slideset
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018Translational pharmacokinetic modelling & simulation of an experimental long-acting injectable formulation of bedaquiline- An Vermeulen, PhDView Slideset
